| 4.81 0.06 (1.26%) | 07-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.94 | 1-year : | 6.94 |
| Resists | First : | 5.09 | Second : | 5.94 |
| Pivot price | 4.87 |
|||
| Supports | First : | 4.72 | Second : | 4.5 |
| MAs | MA(5) : | 4.86 |
MA(20) : | 4.87 |
| MA(100) : | 4.45  |
MA(250) : | 4.74 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 63.2 |
| RSI | RSI(14): 49 |
|||
| 52-week | High : | 11.43 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INTS ] has closed above bottom band by 35.3%. Bollinger Bands are 69.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.87 - 4.9 | 4.9 - 4.93 |
| Low: | 4.72 - 4.75 | 4.75 - 4.79 |
| Close: | 4.79 - 4.85 | 4.85 - 4.9 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Tue, 02 Jul 2024
Portage Biotech Highlights Promising Efficacy and Survival Data Presented on Intensity Therapeutics' INT230-6 (PORT ... - Quantisnow
Sun, 30 Jun 2024
Intensity Therapeutics to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide ... - Quantisnow
Thu, 06 Jun 2024
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely? - Yahoo Finance
Wed, 15 May 2024
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors - PR Newswire
Tue, 14 May 2024
Intensity Therapeutics: A Bargain Late-Stage Company With Remarkable Oncology Drug (INTS) - Seeking Alpha
Fri, 10 May 2024
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 47.3 (%) |
| Held by Institutions | 11.9 (%) |
| Shares Short | 33 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -1.11 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.7 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -110.5 % |
| Return on Equity (ttm) | -734.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.38 |
| PEG Ratio | 0 |
| Price to Book value | 6.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|